<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-four patients with advanced malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> including <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, n = 1), intermediate grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (IGL, n = 12) and high-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (HGL, n = 11) were prepared for syngeneic (n = 2), allogeneic (n = 11) or autologous (n = 11) marrow transplantation with <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, 3 g/m2 every 12h for 12 doses (HDAC) and total body irradiation, 200 cGy daily for 6 days (TBI) to determine toxicity and efficacy </plain></SENT>
<SENT sid="1" pm="."><plain>Eight patients (33%) died from early regimen related toxicity and <z:hpo ids='HP_0000001'>all</z:hpo> eight had a Karnofsky performance score less than or equal to 80 at the start of treatment </plain></SENT>
<SENT sid="2" pm="."><plain>The actuarial probability of disease-free survival was 17% with a 65% probability of relapse at 4 years after transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>Four patients are surviving 2-4 years post-transplant, three transplanted for IGL and one for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>None of the patients transplanted for HGL survived </plain></SENT>
<SENT sid="5" pm="."><plain>The result of this phase II study suggests that HDAC followed by TBI and marrow infusion offers no apparent advantage over <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> + TBI for patients with relapsed advanced malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Earlier transplantation currently is the only demonstrated method of achieving better results </plain></SENT>
</text></document>